Levartovsky Asaf, Yavzori Miri, Fudim Ella, Kopylov Uri, Ben-Horin Shomron, Ungar Bella
Department of Gastroenterology, Sheba Medical Center Tel Hashomer, Tel Aviv University, Tel-Aviv, Israel.
Case Rep Gastroenterol. 2022 Jun 28;16(2):430-434. doi: 10.1159/000525404. eCollection 2022 May-Aug.
Vedolizumab-associated adverse effects, including infusion reactions, are generally uncommon. Less than 5% of patients experience an infusion-related reaction. We report a 67-year-old male with ulcerative colitis under prolonged maintenance therapy who presented with recurring chest pain occurring immediately after consecutive vedolizumab infusions. Medical workup of possible etiologies for chest pain were investigated and excluded. Vedolizumab drug trough levels were negative, accompanied by high detectable levels of anti-vedolizumab antibodies. These findings demonstrate an uncommon case of an infusion reaction to vedolizumab infusion.
维多珠单抗相关的不良反应,包括输液反应,通常并不常见。不到5%的患者会出现输液相关反应。我们报告了一名67岁患有溃疡性结肠炎且正在接受长期维持治疗的男性患者,他在连续输注维多珠单抗后立即出现反复胸痛。对胸痛可能病因进行了医学检查并排除。维多珠单抗药物谷浓度为阴性,同时可检测到高水平的抗维多珠单抗抗体。这些发现证明了一例罕见的维多珠单抗输液反应病例。